Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients
I'm LongbridgeAI, I can summarize articles.Spyglass Pharma released a corporate deck detailing its BIM-IOL System, a long-acting intraocular drug delivery device for glaucoma and ocular hypertension. The system aims to deliver bimatoprost for approximately three years. Clinical data indicates high efficacy in reducing topical therapy reliance and lowering intraocular pressure. The U.S. addressable market is estimated at $13 billion, with significant patient volume projected for cataract surgery. As of June 2026, the company held $234.2 million in cash and equivalents.
- SpyGlass outlined Phase 3 pivotal trials for its BIM-IOL System, designed to deliver about three years of bimatoprost for OAG/OHT. * First-in-human data showed 95% of patients off topical IOP therapy at 36 months; mean IOP fell 37% across doses. * Phase 1⁄2 data showed 98% off topical therapy at 12 months at the intended 78 mcg dose; mean IOP declined 34%. * U.S. addressable market estimated at about USD 13 billion; about 1,000,000 glaucoma or OHT patients projected to undergo cataract surgery in 2025. * Cash, cash equivalents, short-term investments totaled USD 234.2 million as of June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here